Ortho Evra

Ortho Evra is a brand name of ethinyl estradiol/norelgestromin, approved by the FDA in the following formulation(s):

ORTHO EVRA (ethinyl estradiol; norelgestromin - film, extended release; transdermal)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: November 20, 2001
  
  Strength(s): 0.02MG/24HR;0.15MG/24HR ^[RLD]

Has a generic version of Ortho Evra been approved?

No. There is currently no therapeutically equivalent version of Ortho Evra available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ortho Evra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
  Patent 5,876,746
  Issued: March 2, 1999
  Inventor(s): Jona; Janan & Audett; Jay & Singh; Noel
  Assignee(s): Cygnus, Inc.
  Compositions and methods for preventing ovulation in a woman are provided, as well as compositions and methods for female hormone replacement therapy. The compositions can be administered by the use of a transdermal patch. The patch will administer 17-deacetyl norgestimate alone or in combination with an estrogen such as ethinyl estradiol to women via an adhesive matrix of a silicone and/or polyisobutylene.
  
  Patent expiration dates:
  
  
  • November 20, 2015
    
    ✓ 
    Patent use: PREVENTION OF OVULATION IN A WOMAN
    ✓ 
    Drug product
  
  



• 
  Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
  Patent 5,972,377
  Issued: October 26, 1999
  Inventor(s): Jona; Janan & Audett; Jay & Singh; Noel
  Assignee(s): Cygnus, Inc.
  Compositions and methods for preventing ovulation in a woman are provided, as well as compositions and methods for female hormone replacement therapy. The compositions can be administered by the use of a transdermal patch. The patch will administer 17-deacetyl norgestimate alone or in combination with an estrogen such as ethinyl estradiol to women.
  
  Patent expiration dates:
  
  
  • June 7, 2015
    
    ✓ 
    Patent use: PREVENTION OF OVULATION IN A WOMAN
  
  

See also...

• Ortho Evra Consumer Information (Drugs.com)
• Ortho Evra Patch Consumer Information (Wolters Kluwer)
• Ortho Evra Consumer Information (Cerner Multum)
• Ortho Evra Advanced Consumer Information (Micromedex)
• Norelgestromin/Ethinyl Estradiol Patch Consumer Information (Wolters Kluwer)
• Ethinyl estradiol and norelgestromin Consumer Information (Cerner Multum)
• Ethinyl estradiol and norelgestromin Transdermal Advanced Consumer Information (Micromedex)